Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting funding for two preclinical programs and evaluating strategic options. Despite Tecelra’s novelty, Adaptimmune has had to implement cost-saving measures to prioritize the cell therapy’s launch and will be discontinuing funding for two preclinical programs, according to a March 20 press release. Source: Fierce Biotech 20/3/2025